Researchers from the American Institute of Allergy and Infectious Diseases published a paper in the journal Science, claiming that they have developed a new DNA (deoxyribonucleic acid) Zika vaccine. Animal experiments have shown that this vaccine can prevent monkeys from being infected with Zika virus. At present, the vaccine has entered the stage of human clinical trials to verify its safety and effectiveness for humans. Ted Pearson, director of the Institute’s Virus Pathology Department, explained that this vaccine contains a piece of synthetic DNA from Zika virus. After injection into the body, the cells secrete many small particles similar to Zika virus. These particles can Stimulates the immune system to produce an antibody response to prevent Zika virus infection. "This type of DNA vaccine has a successful precedent, and a candidate vaccine for West Nile virus was developed using similar technology a few years ago."
In order to verify the potential efficacy of the DNA Zika vaccine, the researchers injected 6 rhesus monkeys with a dose of a single DNA fragment and 18 monkeys with two DNA fragments. It was found that the monkeys who received a single dose of injection were all infected with Zika virus, but their blood levels of virus were lower than those of the control group that did not receive the DNA vaccine, which proved that the vaccine had produced an antibody response in the macaques; and those who received double doses Of the injected monkeys, 17 were not infected with Zika virus, which proved that this dose was sufficient to form an antibody response against infection.
Zika virus can cause neonatal defects such as microcephaly. According to reports, during the Zika virus outbreak in South America last year, thousands of newborns suffered from congenital microcephaly; as of September 21, the number of Zika infections in Southern California has risen to 43, and there is an urgent need to prevent birth defects. Zika vaccine.
Research has shown that the reason why Zika virus causes neonatal neurodevelopmental defects is that the virus infects the fetus through the mother and attacks its developing neurons. Another researcher, Amish Adaga, an infectious disease expert at the University of Pittsburgh Center for Medicine and Health Safety, said: "Our DNA vaccine can generate an immune response in pregnant women to prevent the fetus from contracting Zika virus and thus avoid birth defects. This The class vaccine is an important innovation in the development of Zika vaccine. Once the human body is clinically proven to be safe and effective, it will become the first commercial DNA vaccine."